Market closed
Neurogene, Inc./$NGNE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Ticker
$NGNE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
107
ISIN
US64135M1053
Website
Neurogene, Inc. Metrics
BasicAdvanced
$210M
-
-$4.35
-
-
Price and volume
Market cap
$210M
52-week high
$18.62
52-week low
$6.88
Average daily volume
328K
Financial strength
Current ratio
21.03
Quick ratio
20.761
Long term debt to equity
2.955
Total debt to equity
4.012
Interest coverage (TTM)
-8,149.55%
Management effectiveness
Return on assets (TTM)
-21.94%
Return on equity (TTM)
-34.97%
Valuation
Price to revenue (TTM)
296.039
Price to book
0.75
Price to tangible book (TTM)
0.75
Price to free cash flow (TTM)
-3.843
Growth
Earnings per share change (TTM)
-524.39%
Neurogene, Inc. News
AllArticlesVideos
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Business Wire·1 day ago
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Business Wire·2 weeks ago
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Neurogene, Inc. stock?
Neurogene, Inc. (NGNE) has a market cap of $210M as of May 10, 2025.
What is the P/E ratio for Neurogene, Inc. stock?
The price to earnings (P/E) ratio for Neurogene, Inc. (NGNE) stock is 0 as of May 10, 2025.
Does Neurogene, Inc. stock pay dividends?
No, Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Neurogene, Inc. dividend payment date?
Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurogene, Inc.?
Neurogene, Inc. (NGNE) does not currently have a Beta indicator.